Quick answer
What do key preclinical studies show about tesamorelin and GH secretion? The central reference is a non-clinical pharmacology and safety evaluation of TH9507, a hGRF(1-44)NH2 analog carrying a trans-3-hexenoyl group on Tyr1, the same modification described on the V8 product page. In rat, dog and human plasma the modification slowed in vitro degradation compared with native hGRF(1-44)NH2; daily repeat administration to pigs, rats and dogs markedly raised plasma GH and IGF-1; and in rats and dogs for up to four months the anabolic effect and the adverse findings seen in dogs were attributed to sustained exposure to supraphysiological GH and IGF-1. Apparent elimination half-life in dogs was 21 to 45 minutes. Laboratory research use only.
A preclinical summary is only useful if it separates what was measured, in which species, from what is often assumed. This article reads the primary non-clinical report on the tesamorelin-type analog and its supporting literature, and distills the findings into a species-by-species view for a researcher planning GH-axis experiments. It does not recommend any use. The hexenoyl chemistry itself is covered in tesamorelin reconstitution and storage and the tesamorelin research overview; the supplied material is on the tesamorelin product page.
Why the molecule was modified: the native GHRH problem
Growth hormone-releasing factor was isolated from human pancreatic tumors that caused acromegaly, and its structure was reported in 1982 (Guillemin 1982; Rivier 1982). The hypothalamic peptide, GHRH, is released into portal blood and acts at the pituitary; a review of its biology summarizes its role in GH secretion (Frohman and Jansson 1986). The difficulty for experiments is stability in plasma. Frohman and colleagues found that when GRH(1-44)-NH2 was incubated with human plasma, the HPLC half-life was 17 minutes, the major product was GRH(3-44)-NH2 with less than 10−3 of the parent activity, and in normal subjects the in vivo half-life of the intact peptide was 6.8 minutes; the results pointed to a plasma dipeptidylaminopeptidase as the inactivating enzyme (Frohman 1986).
That finding defines the design problem. If the first two residues are removed in minutes, a stabilized N-terminus should prolong the half-life. The tesamorelin-type approach is to cap Tyr1 with a trans-3-hexenoyl group while keeping the full 44-residue backbone. The product page describes this cap as increasing resistance to dipeptidyl peptidase-4.
The core non-clinical report
Ferdinandi and colleagues evaluated TH9507, which they describe as hGRF(1-44)NH2 minimally modified by addition of a trans-3-hexenoyl moiety to Tyr1, found to be resistant to dipeptidyl aminopeptidase-IV deactivation (Ferdinandi 2007). Compared with natural hGRF(1-44)NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma and prolonged in vivo plasma elimination kinetics.
| Finding | Species and system | Reported result |
|---|---|---|
| In vitro stability | Rat, dog, human plasma | Degradation slowed compared with natural hGRF(1-44)NH2 |
| Pharmacodynamics | Pigs, rats, dogs; repeat daily intravenous or subcutaneous administration | Plasma GH and IGF-1 markedly increased |
| Sub-chronic safety | Rats and dogs, up to 4 months | Increase in body weight gain, significant but not dose-related, with a biomarker response |
| Tolerability | Rats and dogs | Well tolerated; more pronounced anabolic effect and reversible adverse findings in dogs |
| Dog findings | Repeat daily subcutaneous administration | Liver and kidney findings, anaemia, clinical chemistry and organ weight changes |
| Attributed cause | Dogs | Prolonged exposure to supraphysiological GH and IGF-1 |
| Toxicokinetics | Rats and dogs | Exposure dose related by both routes; apparent elimination half-life in dogs 21 to 45 min |
Two interpretive points matter. The authors attribute the dog findings to the pharmacology, that is, sustained GH and IGF-1 elevation, rather than to an unrelated toxic effect of the peptide. And the half-life of 21 to 45 minutes in dogs, though much longer than the 6.8 minutes reported in humans for native GRH(1-44)-NH2 by a different method, comes from a different species and assay, so the two numbers are not a like-for-like fold change.
What this means for GH-axis experiments
The report supports three design principles. First, GH and IGF-1 are the pharmacodynamic markers: both rose, in three species, so an experiment aimed at the pituitary–GH axis should plan to measure both and should consider that IGF-1 reflects exposure over a longer window than GH. Second, species differ in sensitivity; the more pronounced effects were reported in dogs, and rats and pigs did not show the same adverse pattern, so cross-species extrapolation needs caution. Third, duration of exposure can matter more than peak exposure, because the findings the authors flagged were linked to prolonged elevation, a reminder that sampling schedule and washout belong in the protocol.
| Planning question | Evidence-based note |
|---|---|
| Which readouts? | Plasma GH and IGF-1, each with its own time scale |
| Which species? | The report covers pigs, rats and dogs; effects differed in magnitude |
| How long? | Exposure for up to four months was studied in rats and dogs; shorter designs cannot see chronic changes |
| Which comparator? | Native hGRF(1-44)NH2 for stability; a shorter analog for chain-length questions |
| How to confirm identity of the material? | Mass and HPLC from the certificate where published, plus the formula and sequence on the product page |
Comparing with shorter GHRH analogs
Because tesamorelin is built on the full 44 residues, it differs from analogs based on the first 29 residues, which retain the biologically active region but are shorter. The chain-length comparison is the subject of tesamorelin vs CJC-1295, tesamorelin vs sermorelin and CJC-1295 vs sermorelin. In a stability experiment, the useful comparator for the hexenoyl cap is native GRH(1-44)-NH2 itself; for a chain-length question the comparator is a 1-29 analog. The product page lists the formula C221H366N72O67S, supplied as a 10 mg lyophilized powder with purity stated as ≥98% by HPLC.
How to design a plasma-stability comparison
The simplest experiment that mirrors the report is an in vitro plasma incubation. Spike the modified peptide and native GRH(1-44)-NH2 into plasma from the species of interest at the same molar concentration, hold at 37 °C, withdraw samples at set times, stop the enzymatic reaction at once (acid or organic solvent precipitation, or a protease inhibitor), and quantify the intact peptide by HPLC or LC-MS. Frohman’s work shows why HPLC is the right tool: the immunoreactive half-life was 63 minutes by radioimmunoassay while the intact-peptide half-life by HPLC was 17 minutes, because the inactive GRH(3-44)-NH2 product still cross-reacted in the immunoassay (Frohman 1986). An assay that cannot separate the intact peptide from its truncated product will overestimate stability.
| Element | Reason |
|---|---|
| Same molar concentration for both peptides | Avoids confounding enzyme saturation with stability |
| Plasma from each species of interest | Dipeptidyl peptidase activity differs between species |
| Time-zero sample | Corrects for immediate adsorption |
| Immediate quench | Stops degradation after sampling |
| Chromatographic separation of the 3-44 product | Distinguishes intact from inactive fragment |
| DPP-4 inhibitor arm | Confirms the pathway responsible |
Fit ln(concentration) against time to extract the elimination rate constant k, and compute the half-life as 0.693 / k. Report the matrix, temperature, concentration and assay method with the number, since all of them change it.
Reading the safety findings as pharmacology
The report’s adverse findings in dogs are best read as the consequence of the pharmacology: a GH-axis agonist given repeatedly keeps GH and IGF-1 elevated, and sustained elevation of those hormones has well-known organ effects in animals. This reading matters for experiment design in two ways. It means that a long-term in vivo design with a GHRH analog should include IGF-1 monitoring and a plan for the duration of exposure. And it means that dose-response and washout data are as important as peak response. The paper itself describes the dog adverse effects as reversible and reports that exposure was dose related by both routes.
It is also a reminder that stabilization has a cost in the experimental sense: a more durable ligand gives longer receptor occupancy, which changes feedback dynamics. A native peptide with a half-life of minutes imposes pulsatile stimulation, whereas a more durable analog can approximate continuous stimulation. Which is desired depends on the question, and the choice of analog should be justified in the methods.
Handling points that follow from the structure
The sequence contains a methionine, asparagine and glutamine residues, so oxidation and deamidation are relevant, and a large peptide can aggregate when agitated. Oxidation and deamidation pathways are reviewed in general terms for peptide and protein pharmaceuticals (Manning 2010). The product page states storage at 2–8 °C with −20 °C for long-term holding and protection from heat, moisture and light. Low-binding plastic helps for dilute solutions (Goebel-Stengel 2011). Related handling guides are tesamorelin reconstitution and storage and how to reconstitute a lyophilized peptide. Verification is covered in tesamorelin purity testing, and certificates, where published, are in the COA library.
Reporting preclinical GH-axis data carefully
When citing these findings, attach the species, route and duration to every statement. “Plasma GH and IGF-1 markedly increased in pigs, rats and dogs after daily repeat intravenous or subcutaneous administration” is a defensible sentence; “tesamorelin raises GH” without qualifiers is not. Distinguish the compound tested (TH9507, as named in the paper) from material you use, and cite the product page and certificate for the latter. Keep the pharmacology and the safety findings separate in the text, because the paper links the dog findings to sustained exposure rather than to an independent toxic mechanism, and a reader should be able to see that link.
For concentration work use C = m / (MW × V) and C1V1 = C2V2, and the reconstitution calculator for vial arithmetic. For the broader catalog see the shop page. All material is for laboratory research use only; not for human or animal consumption.
Frequently asked questions
What is TH9507?
The designation used in the non-clinical report for hGRF(1-44)NH2 modified with a trans-3-hexenoyl group on Tyr1, the same modification described on the V8 tesamorelin product page.
Why was native GHRH modified?
Native GRH(1-44)-NH2 is inactivated in plasma within minutes by a dipeptidylaminopeptidase that removes the first two residues, giving a product with less than 1/1000 of the activity.
Did the hexenoyl group improve stability?
The report states it slowed in vitro degradation in rat, dog and human plasma and prolonged in vivo plasma elimination kinetics compared with the natural peptide.
Which species were studied?
Pigs, rats and dogs for pharmacodynamics; rats and dogs for sub-chronic studies of up to four months.
What happened to GH and IGF-1?
Both markedly increased in pigs, rats and dogs after repeat daily intravenous or subcutaneous administration.
What was the elimination half-life in dogs?
The apparent elimination half-life ranged from 21 to 45 minutes.
What did the authors attribute the dog findings to?
Prolonged exposure to supraphysiological GH and/or IGF-1.
Are the half-life figures comparable between species?
No. They come from different species, matrices and assay methods and should not be turned into a fold change.
How does tesamorelin differ from 1-29 analogs?
It retains all 44 residues, whereas sermorelin and CJC-1295 are based on the first 29.
What does the product page state?
A 10 mg lyophilized powder with purity stated as ≥98% by HPLC, stored at 2–8 °C with −20 °C for long-term holding.
Related reading: Tesamorelin Quality Standards for Research Labs, Tesamorelin History: From GHRH Discovery to Analog.
References
- Ferdinandi ES, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. doi:10.1111/j.1742-7843.2007.00008.x
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the Tyr1-Ala2 bond. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
- Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223-253. doi:10.1210/edrv-7-3-223
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
